Document Detail

Cardiovascular responses to intrathecal neuropeptide gamma in conscious rats: receptor characterization and mechanism of action.
MedLine Citation:
PMID:  8789376     Owner:  NLM     Status:  MEDLINE    
1. In the conscious rat, cardiovascular responses to intrathecally (i.t.) administered neuropeptide gamma (NP gamma) were studied prior to and after the i.t. pretreatment with selective antagonists at NK1 ((+/-)-CP 96345 and RP 67580), NK2 (SR 48968) and NK3 (R 486) receptors. Pretreatment with a mixture of peptidase inhibitors (phosphoramidon, captopril, bacitracin, phenanthroline) was also tested to ascertain whether or not the effect of NP gamma was mediated by a metabolite. The involvement of peripheral catecholamines was examined with intravenous injection of alpha-adrenoceptor (phentolamine) and beta-adrenoceptor (propranolol) antagonists. 2. NP gamma (0.078-78 nmol) induced dose-dependent increases in heart rate (HR) and mean arterial blood pressure (MAP). The highest dose of 78 nmol did not induce an increase of MAP greater than that with 7.8 nmol but was preceded by a transient decrease of MAP (1-3 min). No desensitization was observed when three injections of 7.8 nmol NP gamma were given at 90 min intervals. 3. Cardiovascular and behavioural (biting/scratching) effects evoked by 0.78 nmol NP gamma were significantly reduced by the NK1 antagonists, (+/-)-CP 96345 (65 nmol) or RP 67580 (7.8 and 78 nmol). However, cardiovascular responses to NP gamma were not affected by (+/-)-CP 96345 (6.5 nmol), SR 48968 (7.8 and 78 nmol) or R 486 (25 nmol). Pretreatment with peptidase inhibitors significantly enhanced the cardiovascular and behavioural responses to NP gamma. 4. The pressor response to 7.8 nmol NP gamma was converted to a vasodepressor response by pretreatment with phentolamine (2 mg kg-1, i.v.) while the chronotropic response was markedly reduced by propranolol (2 mg kg-1, i.v.). 5. These results suggest that the cardiovascular responses to i.t. NP gamma are mediated by NK1 receptors in the spinal cord leading to the peripheral release of catecholamines from sympathetic fibres or the adrenal medulla. It is unlikely that the spinal action of NP gamma results from its metabolic conversion into neurokinin A or another major metabolite.
P Poulat; J de Champlain; R Couture
Related Documents :
8783036 - Young children's cardiovascular stress responses predict resting cardiovascular functio...
11346496 - The physiology behind exercise testing.
1565926 - Neural influence on cardiovascular and endocrine responses to static exercise in humans.
22964856 - Determination of friction and pulling forces during a weighted sled pull.
3431376 - Effect of beta-blockade on exercise core temperature in coronary artery disease patients.
8852626 - Oxygen- and pressure-dependent functional capillary density in rabbit tenuissimus muscle.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  117     ISSN:  0007-1188     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  1996 Jan 
Date Detail:
Created Date:  1997-04-09     Completed Date:  1997-04-09     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  250-7     Citation Subset:  IM    
Department of Physiology, Université de Montréal, Québec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Behavior, Animal / drug effects
Blood Pressure / drug effects
Dose-Response Relationship, Drug
Heart Rate / drug effects
Hemodynamics / drug effects*
Injections, Spinal
Neuropeptides / administration & dosage,  pharmacology*
Peptide Fragments / administration & dosage,  pharmacology*
Protease Inhibitors / pharmacology
Rats, Wistar
Receptors, Neurokinin-1 / antagonists & inhibitors
Receptors, Neurokinin-2 / antagonists & inhibitors
Receptors, Neurokinin-3 / antagonists & inhibitors
Receptors, Neuropeptide / antagonists & inhibitors*,  metabolism*
Tachykinins / administration & dosage,  antagonists & inhibitors,  pharmacology*
Reg. No./Substance:
0/Neuropeptides; 0/Peptide Fragments; 0/Protease Inhibitors; 0/Receptors, Neurokinin-1; 0/Receptors, Neurokinin-2; 0/Receptors, Neurokinin-3; 0/Receptors, Neuropeptide; 0/Tachykinins; 114882-65-4/tachykinin neuropeptide gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of it...
Next Document:  Alterations in the force-frequency relationship by tert-butylbenzohydroquinone, a putative SR Ca2+ p...